Drug intelligence / Profile preview

BION-202

Development stage: Preclinical
Lead developer: Biond Biologics
Modality: Antibody-Based Therapeutics

Overview

BION-202 is a first-in-class therapeutic antibody developed by Biond Biologics that functions as a macrophage activator to enhance phagocytosis, with the aim of boosting innate anti-tumor immunity in cancer patients.[7][11] Designed to target immuno-oncology pathways distinct from classical T cell–centric checkpoint inhibitors, BION-202 is intended for the treatment of neoplasms, and is being advanced from preclinical development toward early-stage clinical trials as part of Biond’s immuno-oncology pipeline.[5][7][11]

Targets

LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1)

Beyond the preview

Go deeper on BION-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BION-202.

Explore the full profile